Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AY4166 Phase III Long-term Study in Type 2 Diabetes Patients
jRCT2080221882Phase 3
- Sponsor
- Ajinomoto
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nateglinide in type 2 diabetes mellitus (T2DM), sponsored by Ajinomoto.
02
Drugs
nateglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221882.